Strainsforpains, Inc., a leading cannabinoid-based retail and wholesale drug commercialization specialist, has recently announced a significant partnership with Cannabis Science, Inc. This international retail and wholesale cannabinoid drug commercialization agreement is set to revolutionize the industry.
Cannabis Science, known for its Harvard Award Winning Cancer Killing Success, brings a robust pipeline of therapeutic and critical ailment cannabinoid drugs to the table. Strainsforpains, on the other hand, has already achieved remarkable sales growth with its proven cannabinoid-based product pipeline.
One of the highlights of this partnership is the Cannabis Science CBN US Patent protected product pipeline, which targets sleep deprivation, PTSD, and other neurological conditions. With the sleep deprivation and PTSD markets combined valued at over $500 billion worldwide, the potential for fulfilling this demand is immense.
Strainsforpains has strategically established partnerships with hemp farmers in Virginia and Pennsylvania, ensuring a resilient and optimized supply chain. The company’s 7-acre Pennsylvania facility and New York City locations serve as storage hubs for its diversified cannabinoid-based products.
Initial orders, including over 3000 units of CBD body cream, are already set to be distributed across pharmacies and wellness centers in the Tri State area. Notable locations such as Central Pharmacy of Brooklyn, DIV Pharmacy of Flatbush, and Kyse Pharmacy of Rockaway are among the recipients. The positive responses from stores, dispensaries, and customers have further motivated Strainsforpains to expand its CBD product line in 2024.
Cannabis Science’s Harvard Award Winning Cancer Killing Drug Development is another significant aspect of this partnership. The company’s top CSi-Cancer Killing Drug Valuation targets, including Stage 4 Lung Cancer, Pancreatic Cancer, Stage 4 Breast Cancer, Basil Cell Carcinoma (Skin Cancer), Brain Cancer, and Kaposi’s Sarcoma, hold great promise. Oncology drugs are the fastest-growing category in pharma, with forecasters predicting that the top 15 drugs will generate nearly $90 billion by 2022.
With this groundbreaking collaboration, Strainsforpains and Cannabis Science are poised for rapid growth in the coming years. The companies’ combined expertise, innovative product pipelines, and strategic partnerships position them as leaders in the cannabinoid-based retail and wholesale drug market. Both companies are dedicated to bringing effective and safe cannabinoid products to market, addressing critical medical needs and improving patient outcomes.
For more information, please visit Strainsforpains’ official website at [http://www.strainsforpains.com/](http://www.strainsforpains.com/) and Cannabis Science’s official website at [https://www.cannabisscience.com/](https://www.cannabisscience.com/).